Research programme: motilin receptor agonists - RaQualia Pharma

Drug Profile

Research programme: motilin receptor agonists - RaQualia Pharma

Alternative Names: RQ 00201894

Latest Information Update: 20 Oct 2016

Price : $50

At a glance

  • Originator Pfizer
  • Developer RaQualia Pharma
  • Class Indoles; Small molecules
  • Mechanism of Action Motilin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Gastrointestinal disorders

Most Recent Events

  • 20 Oct 2016 Preclinical development is ongoing for Gastrointestinal disorders (Gastroparesis, Functional dyspepsis and Post-operative ileus) (RaQualia Pharma pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in Japan (PO)
  • 26 Oct 2015 RaQualia Pharma receives patent allowance for motilin receptor agonist in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top